Publications by authors named "Timo Behlendorf"

Claim this Profile
I
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.
Petra Langerbeins, Sandra Robrecht, Pascal Nieper, Paula Cramer, Moritz Fürstenau, Timo Behlendorf

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO).
Sabrina Jotschke, Susann Schulze, Nadja Jaekel, Beatrice Ludwig-Kraus, Robby Engelmann, Timo Behlendorf

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.
Tobias Dechow, Ali Aldaoud, Timo Behlendorf, Wolfgang Knauf, Henning Eschenburg

Eur J Haematol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic work-up for the detection of malnutrition in hospitalized cancer patients.
Camilla Leithold, Karin Jordan, Franziska Jahn, Timo Behlendorf, Judith Schaffrath

J Community Support Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis.
Franziska Jahn, Karin Jordan, Timo Behlendorf, Cordula Globig, Hans-Joachim Schmoll

Oncology· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.
Maxi Wass, Timo Behlendorf, Bärbel Schädlich, Anja Mottok, Andreas Rosenwald

Eur J Haematol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy.
Karin Jordan, Iris Kinitz, Wieland Voigt, Timo Behlendorf, Hans-Heinrich Wolf

Eur J Cancer· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anthracycline extravasation injuries: management with dexrazoxane.
Karin Jordan, Timo Behlendorf, Franziska Mueller, Hans-Joachim Schmoll

Ther Clin Risk Manag· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-(4-(Tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II): a novel platinum compound that overcomes cisplatin resistance and induces apoptosis by mechanisms different from that of cisplatin.
Andrea Dietrich, Thomas Mueller, Reinhard Paschke, Bernd Kalinowski, Timo Behlendorf

J Med Chem· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venous access ports: frequency and management of complications in oncology patients.
Karin Jordan, Timo Behlendorf, Alexey Surov, Thomas Kegel, Gita Maher

Onkologie· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis